Abcellera Biologics Inc (ABCL)

$3.90 +0.47 (13.70%)
Market Cap 1.03B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 6,345,500
Avg Vol 4,117,694
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 19%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
SilverBolt
SilverBolt Jan. 7 at 12:19 AM
~No question about it, @CoralSharkie absolutely ran last year. Completely on another level 🔥 If you’re not following yet, hit that FOLLOW button. It’s one click, totally free. Much love, appreciate you bro 🙏 $ABCL $LAR $ATGL $HL looking nice
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 7 at 12:00 AM
$ABCL Abcellera $ABCL acknowledged by Gilead in their 2025 published papers: "The authors gratefully acknowledge Abcellera for their B-cell screening contribution in discovery of the antibodies discussed in this publication" "We acknowledge AbCellera for the contribution of their B cell screening platform in the discovery of the antibodies discussed in this publication" https://www.tandfonline.com/doi/pdf/10.1080/19420862.2025.2562998
0 · Reply
Stackdoe1
Stackdoe1 Jan. 6 at 9:52 PM
$ABCL $10
0 · Reply
RunnerSignals
RunnerSignals Jan. 6 at 9:13 PM
$RKLB $NFE $AGL $AXTI $ABCL Market Warriors started down but fought back hard
0 · Reply
hagarone
hagarone Jan. 6 at 8:53 PM
$ABCL Wrong. Volume is significantly above average.
0 · Reply
Chebsmcgee
Chebsmcgee Jan. 6 at 8:46 PM
$ABCL also wouldn’t be surprised to see 4.5 range again, loves hitting that and coming back so we can add more
0 · Reply
inflect1on
inflect1on Jan. 6 at 8:38 PM
$ABCL wow that’s a big candle.. no shot it doesn’t retrace a bit right?
0 · Reply
DeMampCamp
DeMampCamp Jan. 6 at 8:38 PM
$ABCL Coming up on the 50 day MA, around $3.95, not so sure we'll cross it today, but if it happens tomorrow we might be ready to close that gap at $4.37 and head back to the 5s!! Great day, folks!
1 · Reply
Ed_Ng
Ed_Ng Jan. 6 at 8:33 PM
$ABCL volume is very very low. Will down to 3.3-3.4 again
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 6 at 8:21 PM
$ABCL GO BABY GO
0 · Reply
Latest News on ABCL
AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 19 days ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 4 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 4 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 6 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 2 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 3 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 4 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 4 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 11 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

SilverBolt
SilverBolt Jan. 7 at 12:19 AM
~No question about it, @CoralSharkie absolutely ran last year. Completely on another level 🔥 If you’re not following yet, hit that FOLLOW button. It’s one click, totally free. Much love, appreciate you bro 🙏 $ABCL $LAR $ATGL $HL looking nice
0 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 7 at 12:00 AM
$ABCL Abcellera $ABCL acknowledged by Gilead in their 2025 published papers: "The authors gratefully acknowledge Abcellera for their B-cell screening contribution in discovery of the antibodies discussed in this publication" "We acknowledge AbCellera for the contribution of their B cell screening platform in the discovery of the antibodies discussed in this publication" https://www.tandfonline.com/doi/pdf/10.1080/19420862.2025.2562998
0 · Reply
Stackdoe1
Stackdoe1 Jan. 6 at 9:52 PM
$ABCL $10
0 · Reply
RunnerSignals
RunnerSignals Jan. 6 at 9:13 PM
$RKLB $NFE $AGL $AXTI $ABCL Market Warriors started down but fought back hard
0 · Reply
hagarone
hagarone Jan. 6 at 8:53 PM
$ABCL Wrong. Volume is significantly above average.
0 · Reply
Chebsmcgee
Chebsmcgee Jan. 6 at 8:46 PM
$ABCL also wouldn’t be surprised to see 4.5 range again, loves hitting that and coming back so we can add more
0 · Reply
inflect1on
inflect1on Jan. 6 at 8:38 PM
$ABCL wow that’s a big candle.. no shot it doesn’t retrace a bit right?
0 · Reply
DeMampCamp
DeMampCamp Jan. 6 at 8:38 PM
$ABCL Coming up on the 50 day MA, around $3.95, not so sure we'll cross it today, but if it happens tomorrow we might be ready to close that gap at $4.37 and head back to the 5s!! Great day, folks!
1 · Reply
Ed_Ng
Ed_Ng Jan. 6 at 8:33 PM
$ABCL volume is very very low. Will down to 3.3-3.4 again
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 6 at 8:21 PM
$ABCL GO BABY GO
0 · Reply
Chebsmcgee
Chebsmcgee Jan. 6 at 8:03 PM
$ABCL god damn I get paid next week couldn’t it wait just a bit longer
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Jan. 6 at 7:59 PM
$ABCL
0 · Reply
PeteyV
PeteyV Jan. 6 at 7:53 PM
$ABCL weird move today. Freshly filed SEC filings simply show $3.42 call options being given to the directors at zero cost (nothing exercised). Did the market misinterpret these neutral transactions as bullish? Or was it something else material that we're not aware of?
1 · Reply
Ed_Ng
Ed_Ng Jan. 6 at 7:53 PM
$ABCL sorry what? Still in the range 3.8-3.3. swing trade heaven and long term short. Easy money.
1 · Reply
AGC_Trader
AGC_Trader Jan. 6 at 7:50 PM
$ABCL is it aiming to break the $4 wall today?
0 · Reply
estatebuyersmia
estatebuyersmia Jan. 6 at 7:40 PM
$ABCL VINDICATION DAY, SORRY ED
0 · Reply
hitmongreen
hitmongreen Jan. 6 at 7:31 PM
$ABCL 🤔
0 · Reply
50bps
50bps Jan. 6 at 7:29 PM
$ABCL 👀👀
1 · Reply
PorkchopSquats
PorkchopSquats Jan. 6 at 7:29 PM
$ABCL
0 · Reply
jgalt284gmailcom
jgalt284gmailcom Jan. 6 at 6:44 PM
$ABCL Dragon, which options did they buy? Strike? Date?
1 · Reply
Stocktradesmoon
Stocktradesmoon Jan. 6 at 6:31 PM
$ABCL Abcellera $ABCL was acknowledged in a paper published by Gilead in 2025. "We deeply thank Abcellera, a B-cell screening specialist company that contributed to discovering the antibodies mentioned in this paper."
1 · Reply
Chebsmcgee
Chebsmcgee Jan. 6 at 6:29 PM
$ABCL
0 · Reply